Eliquis Dosing for Atrial Fibrillation
For stroke prevention in non-valvular atrial fibrillation, the standard dose of Eliquis (apixaban) is 5 mg orally twice daily, with dose reduction to 2.5 mg twice daily ONLY if the patient meets at least TWO of the following three criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1
Standard Dosing Algorithm
Start with 5 mg twice daily for all patients with non-valvular atrial fibrillation unless dose reduction criteria are met 1.
Dose Reduction Criteria (Must Meet ≥2 of 3)
Reduce to 2.5 mg twice daily if the patient has at least TWO of:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Critical Dosing Principles
Do not reduce the dose if only ONE criterion is met. The ARISTOTLE trial demonstrated that patients with only one dose-reduction criterion who received standard dose apixaban (5 mg twice daily) had similar efficacy and safety compared to those with no criteria, with consistent benefits over warfarin 6. Patients with isolated advanced age, low body weight, or renal dysfunction showed no increased bleeding risk with standard dosing when only one criterion was present.
Underdosing is common and potentially harmful. Real-world data shows that approximately 36% of patients receive inappropriately reduced doses 7. While underdosing may not dramatically increase stroke risk, patients receiving reduced doses (whether appropriately or inappropriately) have significantly higher rates of major bleeding compared to standard dosing (HR 1.66 and 1.51 respectively) 7.
Renal Function Considerations
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Continue 5 mg twice daily unless the patient also meets at least one other dose-reduction criterion (age ≥80 or weight ≤60 kg) 3, 8, 4
- Serum creatinine ≥1.5 mg/dL alone is insufficient for dose reduction
Special Renal Scenario
For patients with serum creatinine <1.5 mg/dL but eGFR <50 mL/min who meet one other criterion (age ≥80 or weight ≤60 kg), Asian population data suggests reduced dose (2.5 mg twice daily) may be preferred, though this represents an area of clinical judgment 9.
End-Stage Renal Disease on Dialysis
- 5 mg twice daily is the standard dose
- Reduce to 2.5 mg twice daily only if age ≥80 years OR body weight ≤60 kg 10, 1
- Note: Only TWO criteria apply in dialysis patients (age and weight), not serum creatinine
Severe Renal Impairment (CrCl 15-29 mL/min)
- Very limited trial data exists for this population 3, 8
- If used, apply the standard dose-reduction criteria (≥2 of 3 criteria)
Common Pitfalls to Avoid
Do not reduce dose based on age alone, even in patients ≥80 years. Two criteria must be met 1.
Do not reduce dose based on creatinine clearance calculations alone. The dose-reduction criterion is serum creatinine ≥1.5 mg/dL, NOT creatinine clearance thresholds 3, 4, 5.
Do not use body mass index (BMI) for dosing decisions. The criterion is actual body weight ≤60 kg 1.
Avoid prophylactic dose reduction in "high-risk" patients who don't meet formal criteria. This increases bleeding risk without proven benefit 7.
Evidence Base
The ARISTOTLE trial (18,201 patients) demonstrated that apixaban 5 mg twice daily was superior to warfarin for stroke prevention (HR 0.79) with significantly less major bleeding (HR 0.69) and intracranial hemorrhage (HR 0.51) 2, 4. The dose-reduction strategy to 2.5 mg twice daily for patients meeting ≥2 criteria was prospectively defined and validated within this trial 2.
Recent 2024 guidelines from both ACC/AHA/HRS 4 and ESC/EACTS 5 consistently recommend these dose-reduction criteria, emphasizing that reduced dosing should not be used unless patients meet the specified thresholds to prevent underdosing and avoidable thromboembolic events 5.